Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 28%
Buy 56%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is well-positioned for long-term growth with its diverse portfolio of immunology and oncology drugs. Potential drugs in the pipeline, such as ABBV-319 and ABBV-519, could provide additional growth opportunities. Skyrizi, one of AbbVie's key drugs, continues to demonstrate strong sales growth and the recent acquisition of Allergan further strengthens the company's aesthetics portfolio. Risks to the positive outlook include potential pricing pressure, clinical setbacks, and the impact of tariffs on international sales.

Bears say

AbbVie is showing strong sales and earnings performance, but this is likely unsustainable as it heavily depends on the success of its key franchises. The company's acquisitions in aesthetics, neuroscience, and oncology show a lack of focus and could potentially lead to overspending in the long term. Additionally, while the company has several upcoming catalysts, there is no guarantee that these will translate into success, creating a level of uncertainty in the company's future.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 28% of analysts recommend a Strong Buy, 56% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $256.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $256.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.